MMJ PhytoTech Ltd To Commence Phase 1 Clinical Study Late 2015

Sydney, Aug 24, 2015 AEST (ABN Newswire) - MMJ PhytoTech Limited (ASX:MMJ) is pleased to announce that its subsidiary, PhytoTech Therapeutics, has received official National approval in Israel to commence a Phase I Clinical Study to assess the safety and performance of its proprietary oral capsule formulations.

Highlights

- First Clinical Study ("Study") approval for MMJ PhytoTech Limited ("MMJ" or the "Company") and key milestone in implementation of the Company’s 'Farm to Pharma' strategy

- Study to be conducted by MMJ subsidiary, PhytoTech Therapeutics and will focus on testing the safety and performance of its proprietary oral capsule formulations
- Approval received by all relevant bodies and allows Study to be conducted in Israel

- Initial stability studies have indicated an extended shelf life of the oral capsule formulation at room temperature, providing the potential to increase market share by lower product...

Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.


URL: 
http://www.abnnewswire.net/press/en/80734/MMJ_PhytoTech_Ltd_(ASX_MMJ)_To_Commence_Phase_1_Clinical_Study_Late_2015.html